Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Master protocol of next-generation NY-ESO-1/LAGE-1a TCR-engineered autologous T-cell therapies in advanced solid tumors
NL-OMON52650Completed
- Sponsor
- GSK
- Start
- Dec 2021
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Open-label trial of NY-ESO-1/LAGE-1a TCR-engineered T cells and GSK3845097 in non-small cell lung cancer (NSCLC), synovial sarcoma (SS) and Myxoid/round cell liposarcoma (MRCLS) (2 arms), sponsored by GSK. Primary endpoints: Dose-limiting toxicities and Adverse events and serious adverse events of special interest. Started Dec 2021; status: completed.
02
Drugs
NY-ESO-1/LAGE-1a TCR-engineered T cellsGSK3845097
03
Conditions
non-small cell lung cancer (NSCLC)synovial sarcoma (SS)Myxoid/round cell liposarcoma (MRCLS)
Beyond the preview
Go deeper on NL-OMON52650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52650.